NCT02607202View on ClinicalTrials.gov

A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

May 4, 2021

Study Completion Date

January 31, 2022

Conditions

Unknown Primary Tumors

Interventions

DRUG

nab-paclitaxel

DRUG

Carboplatin

DRUG

Gemcitabine

Trial Locations (10)

10060

Investigative Clinical Oncology (Oncologia Medica 2), Candiolo

10126

A.O.U S.Giovanni Battista, Torino

Unknown

AOU Policlinoco S Orsola - Malpighi, Bologna

Ospedali Galliera, Genova

Istituto Europeo di Oncologia - IEO, Milan

Istituto Nazionale dei Tumori, Milan

Ospedale Niguarda Cà Granda, Milan

Istituto Oncologico Veneto - IOV, Padua

Fondazione IRCCS Policlinico San Matteo, Pavia

Policlinico Universitario Campus Biomedico, Roma

All Listed Sponsors

lead

Fondazione del Piemonte per l'Oncologia

OTHER

NCT02607202 - A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) | Biotech Hunter | Biotech Hunter